Literature DB >> 30809863

Inverse association between statin use and head and neck cancer: Population-based case-control study in Han population.

Li-Ting Kao1,2,3, Shih-Han Hung4,5, Pai-Feng Kao6, Ju-Chi Liu6,7, Herng-Ching Lin2,8.   

Abstract

BACKGROUND: This case-control study aimed to find the relationship between prior statin use and head and neck cancer occurrence using a large population-based database.
METHODS: This study used claims data from the Taiwan Longitudinal Health Insurance Database. We included 5515 patients with head and neck cancer as cases and 5515 propensity score-matched patients without head and neck cancer as controls. Conditional logistic regressions were performed to investigate the relationship between head and neck cancer and prior statin exposure.
RESULTS: Of the 11 030 total sampled patients, 16.95% had previously received prescriptions for statins. In addition, statin exposure was found in 15.99% of cases and 17.91% of controls. The logistic regression also revealed that the adjusted odds ratio of prior statin exposure for cases was 0.86 (95% confidence interval: 0.77-0.95) compared to propensity score-matched controls.
CONCLUSION: This study found an inverse association between statin usage and head and neck cancer occurrence.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; epidemiology; head and neck cancer; hyperlipidemia; statin

Year:  2019        PMID: 30809863     DOI: 10.1002/hed.25501

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Metabolic disorders and the risk of head and neck cancer: a protocol for a systematic review and meta-analysis.

Authors:  Alexander Gormley; Charlotte Richards; Francesca Spiga; Emily Gray; Joanna Hooper; Barry Main; Emma E Vincent; Rebecca Richmond; Julian Higgins; Mark Gormley
Journal:  BMJ Open       Date:  2022-05-04       Impact factor: 3.006

2.  Effects of the Prior Use of Statins on Head and Neck Cancer Risk: A Hospital-Based Case-Control Study.

Authors:  Constanza Saka-Herrán; Enric Jané-Salas; Antonio Mano-Azul; Aina Torrejón-Moya; Albert Estrugo-Devesa; José López-López
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-06

3.  Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.

Authors:  Mark Gormley; James Yarmolinsky; Tom Dudding; Kimberley Burrows; Richard M Martin; Steven Thomas; Jessica Tyrrell; Paul Brennan; Miranda Pring; Stefania Boccia; Andrew F Olshan; Brenda Diergaarde; Rayjean J Hung; Geoffrey Liu; Danny Legge; Eloiza H Tajara; Patricia Severino; Martin Lacko; Andrew R Ness; George Davey Smith; Emma E Vincent; Rebecca C Richmond
Journal:  PLoS Genet       Date:  2021-04-22       Impact factor: 5.917

4.  Statin use and head and neck squamous cell carcinoma outcomes.

Authors:  Kayla R Getz; Emily Bellile; Katie R Zarins; Cailey Rullman; Steven B Chinn; Jeremy M G Taylor; Laura S Rozek; Gregory T Wolf; Alison M Mondul
Journal:  Int J Cancer       Date:  2020-12-15       Impact factor: 7.316

Review 5.  Review of Under-Recognized Adjunctive Therapies for Cancer.

Authors:  Mary E Money; Carolyn M Matthews; Jocelyn Tan-Shalaby
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

6.  The association between inflammatory biomarkers and statin use among patients with head and neck squamous cell carcinoma.

Authors:  Kayla R Getz; Emily Bellile; Katie R Zarins; Steven B Chinn; Jeremy M G Taylor; Laura S Rozek; Gregory T Wolf; Alison M Mondul
Journal:  Head Neck       Date:  2022-03-25       Impact factor: 3.821

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.